MedPath

THYQUIDITY

These highlights do not include all the information needed to use safely and effectively. (levothyroxine sodium) oral solution Initial U.S. Approval: 2000

Approved
Approval ID

67dbca4d-1aea-48f8-a013-c14d5dc75f50

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 14, 2022

Manufacturers
FDA

VistaPharm, Inc.

DUNS: 116743084

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Levothyroxine Sodium

PRODUCT DETAILS

NDC Product Code66689-105
Application NumberNDA214047
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateSeptember 14, 2022
Generic NameLevothyroxine Sodium

INGREDIENTS (6)

CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
LEVOTHYROXINE SODIUMActive
Quantity: 100 ug in 5 mL
Code: 9J765S329G
Classification: ACTIR
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
METHYLPARABEN SODIUMInactive
Code: CR6K9C2NHK
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

THYQUIDITY - FDA Drug Approval Details